Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Canaglu to Hit Japan Market on Sept. 3: MTPC, Daiichi Sankyo
August 29, 2014
- Nippon Shinyaku Sets FY2018 Sales Target of 110 Billion Yen, Plans to Focus on Specialty Fields
August 28, 2014
- Novartis Japan Slapped with Warning over Travel Cost Payments for Doctors
August 28, 2014
- MTPC Aims at Over 17% Share for SGLT-2 Inhibitor Canaglu in Japan: Sales Division Head
August 28, 2014
- Otsuka Holdings Takes Aim at 915 Billion Yen Pharma Sales in FY2018 after Abilify Patent Loss
August 27, 2014
- Fixed-Dose Combination HIV Treatment Triumeq Approved in US: ViiV Healthcare
August 27, 2014
- AnGes MG Resumes Development of NF-κB Decoy Oligo Ointment Formulation for Atomic Dermatitis
August 26, 2014
- Chugai to Restrict Use of Alecensa to Medical Institutions, Doctors that Meet Specified Conditions
August 26, 2014
- AnGes MG Revamps US Unit to Prepare for Global PIII Study of Collategene
August 25, 2014
- Janssen Files Anti-HIV Combination Tablet for Approval
August 25, 2014
- Latuda Goes on Sale in UK: Sumitomo Dainippon
August 25, 2014
- Pfizer Japan to Create New Unit for its Innovative Drug Business in December
August 22, 2014
- Nichi-Iko to Launch Own Products in Thailand in October
August 22, 2014
- Carfilzomib Monotherapy Fails to Meet Primary Endpoint in PIII: Amgen, Onyx
August 22, 2014
- MTPC, AZ Ink Research Collaboration Deal in Diabetic Nephropathy
August 21, 2014
- Eisai Files Fycompa for Primary Generalized Tonic-Clonic Seizures in US, Europe
August 21, 2014
- Japan to See Grueling Battle for Free-Price Viagra Generics
August 20, 2014
- Launch of Daiichi Sankyo Espha’s Cravit Generics Not Yet Determined
August 20, 2014
- Daiichi Sankyo Starts PIII Study of Etanercept Biosimilar, Eying Approval in FY2016
August 20, 2014
- Approval Conditions Lifted for Tykerb: GSK
August 20, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…